Under den 6- måneders dobbeltblinde anvendelse forekom følgende bivirkninger i behandlingsgruppen (n=549) med større incidens end i placebogruppen (n=545).
During 6-month double blind exposure the following adverse reactions occurred in the treatment group (n=549) at a greater incidence than placebo (n=545) and were assessed by the investigators as possibly or probably related to Livensa treatment.